Ook in Engels beskikbaar: Knowledge Beats Cancer
JY HET KANKER! 'n Ystervuis beklem jou hart wanneer jy die diagnose hoor. Ná die skok en ontkenning kom die vrae: Wat gaan nou met my gebeur? Wat is my oorlewingskans?
In Kennis Klop Kanker word die pasiënt, en enigeen wat meer van kanker wil weet, ingelig oor alle fasette van kanker:
Wat kanker presies is en hoe kanker ontstaan
Die omvangsyfer en suksesse van kankerterapieë
Belangrikheid van dieet, noodsaaklike gereelde ondersoeke en selfondersoeke
Die vele vertakkinge en benaderinge van moderne terapieë
Moderne behandelingsmetodes en prognose van algemene kankers (29 tipes)
Deurbrake in molekulêre biologie met minder newe-effekte
Beenmurgstamseloorplanting
Mediane oorlewingstatistiek
Alternatiewe, komplementerende en integrerende terapieë
Pasiëntondersteuning, herstel ná mastektomie, kanker by jongmense en kinders, goeie pynkontrole, versorging van pasiënte met gevorderde kanker
Ondersteuning deur gemeenskapsorganisasies
Skrywer se persoonlike perspektief oor lyding en geloofsgenesing
DIE OUTEUR: Albert Stegmann Alberts is 'n onkoloog wat 33 jaar lank met kankerpasiënte gewerk het. Hy het gespesialiseer in al die vertakkings van kankerterapie. Hy is die outeur van verskeie internasionale publikasies.

It started with a simple question: How can we help them? It became an international movement called NEGU: Never Ever Give Up. When Jessica Joy Rees was diagnosed with an inoperable brain tumor at age 11, she chose to focus not on herself but on bringing joy and hope to other children suffering from cancer. During the ten months she battled cancer, she and her family worked in the "Joy Factory" (originally their garage) making JoyJars (R)-packages filled with toys, games, and love for other kids with cancer. Jessie first handed them out personally at the hospital where she was being treated, but the effort blossomed quickly and there were soon thousands of JoyJars (R) being distributed across the United States and to over fifteen countries. Today, more than 100,000 kids have received JoyJars (R), and they continue shipping each week to kids in over 200 children's hospitals and 175 Ronald McDonald Houses. Jessie lost her battle with cancer in January 2012, but her message lives on in the Jessie Rees Foundation, which has become a beacon of hope for families fighting pediatric cancer. Join the movement at www.negu.org.

Your complete resource for handling the physical and emotional effects of breast cancer treatments. At the time of diagnosis, breast cancer patients are faced with many overwhelming decisions about possible treatments. Living with Breast Cancer provides you with an overview of what to expect from testing and treatment, which cancer specialists you may need to see, and common terms to use to help communicate your needs to your team. This empathetic resource full of relatable stories teaches patients and caregivers how to ask the right questions to get the best possible care. The authors explain how to minimize the symptoms and side effects of treatment and outline coping strategies to deal with the stress of breast cancer treatment, including the changes in your body from cancer and its therapies. The book helps readers * make sense of their diagnosis * set goals and prepare for treatment * understand the different types of therapies, tests, and scans * manage the symptoms and side effects of treatment, such as nausea, fatigue, shortness of breath, weight fluctuations, and depression * learn what medications and lifestyle modifications can help with symptoms * live and cope with progressive cancer Living with Breast Cancer is your definitive resource for handling the physical and emotional effects of breast cancer and treatment.

An illuminating guide for those newly diagnosed with prostate cancer as well as their partners and caregivers—one filled with extensive details about diagnosis, treatments, and tips for thriving. The second leading cause of cancer death for men, prostate cancer affects more than a quarter of a million individuals in the United States each year. Most men with prostate cancer will go through the journey from diagnosis through treatment and beyond with a partner and family members by their side. But there are few resources available that address the needs of both those with cancer and their loved ones who want to help. Written in accessible language and backed by the latest scientific research, Prostate Cancer covers • symptoms, diagnosis, and testing; • the full range of treatment options available; • practical tools partners can use to assist their loved one; • advice on managing the side effects of treatment, including incontinence and sexual problems; • tips to help cope with the emotional challenges associated with cancer; • recommendations for keeping healthy with diet, exercise, and mindfulness; and • insights into insurance issues. With three leading experts in urology, surgery, and psychiatry as its coauthors, Prostate Cancer provides the information and guidance you need to better understand the disease, communicate with health care providers, and support yourself and your loved one through treatment and survivorship.

Each year nearly 35,000 men are diagnosed with prostate cancer. Of these, more than 10,000 die from the disease, and figures are rising. But better awareness, earlier diagnosis and more sophisticated treatments can save lives, and have already reduced death rates in some countries. This new edition of Coping Successfully with Prostate Cancer presents the latest research on prostate cancer and describes the many treatments available. Topics include; symptoms and stages of the disease, other prostate problems, the possible influence of diet, geography and viral factors, screening and investigation, including PSA, the decision to treat, or not to treat, treatments, including surgery and radiation therapy, branchytherapy and laser, dealing with advanced prostate cancer, lifestyle measures, coping with sex, research and the future. In this thoroughly updated and positive book, Dr Tom Smith says that it is possible for men with prostate cancer to lead successful, happy and fufilled lives.

Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use. Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.

Standardizing Pharmacology: Assays and Hormones, Volume Two in the Discoveries in Pharmacology series, presents selected articles from historic discoveries that are enhanced with commentary from contemporary scholars who present discussions on the importance of each chapter, along with an updated bibliography on the subject and contributions from a Nobel Prize winner and other pioneers in pharmacology. Academic and industry researchers in pharmacology and medicine, as well as advanced students will find this series a useful teaching tool and launch to new discoveries. Sections cover key discoveries in receptor theory, pharmacological methods and the development of hormone therapy, including J. Parascandola on the development of receptor theory, R.S. Yalow on radioimmunoassay, M. van Rossum and J.T L.A. Hurkmans on bioassays, M. Tausk on androgen therapy and C. Djerassi on oral contraceptives, with commentaries from experts such as T. Hoekfelt and V.C. Jordan.

Epidemiology of Endocrine Tumors brings current data and clinical research into one source for a multidisciplinary audience. The book discusses the prevalence, incidence, etiology, pathology, diagnosis and treatment of various endocrine tumors. With clear and focused writing, it is essential reading for healthcare professionals, endocrinologists, oncologists, and public health professionals. Users will be able to bridge the knowledge gap that exists in the comprehensive coverage surrounding the epidemiology of endocrine tumors. Globally, the prevalence and incidence of endocrine tumors is high. This audience needs a treatise where they can gain a broad overview of endocrine tumors with a focus on epidemiology.

Aptamers Engineered Nanocarriers for Cancer Therapy details the selection technologies, biological characteristics, and clinical uses of aptamer-based nano agents for cancer therapeutics. The book helps facilitate speedy solutions for some of the problems pertaining to the manufacture of nano-aptamers - such as toxicity, thermal stability, cost efficiency, tumor penetration and blood stability. Key chapters cover cell-SELEX technology for aptamer selection, mechanisms of multi-drug resistance of cancer, the relevance of aptamers as anticancer therapies, as well as the broad range of aptamer-functionalized nanostructures available. This book provides exciting insights into this relatively new approach to cancer therapeutics, and will be of interest to materials scientists, biomedical engineers, molecular biologists, biochemists and clinical scientists, with a focus on cancer therapy.

Discoveries in Pharmacology: Volume 1: Nervous system and hormones (2nd Ed.) presents selected articles from the historic Discoveries in Pharmacology series enhanced with commentary from contemporary scholars about the reception and importance of the chapter along with an updated bibliography on the subject with contributions from a Nobel Prize winner and other pioneers in Pharmacology. The Discoveries in Pharmacology series brought acknowledged experts in their fields together to provide first-hand accounts of important pharmacological discoveries discussing the scientific background and stories behind these pivotal moments. They allow a true understanding of the means by which pharmacological discoveries are made. This volume brings forth discussions on key discoveries in psycho- and neuro-pharmacology, haemodynamics, and hormones including chapters on antipsychotic agents by Nobel winner Anders Carlsson, Willy Haefely on benzodiazepine, and butyrophenone-type neuroleptics by P. A. J. Janssen and J. P. Tollenaere. Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area will find this series a useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies. This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.

Targeted Cancer Imaging: Design and Synthesis of Nanoplatforms based on Tumour Biology reviews and categorizes imaging and targeting approaches according to cancer type, highlighting new and safe approaches that involve membrane-coated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells, all with the goal of pointing the way to developing precise targeting and multifunctional nanotechnology-based imaging probes in the future. This book is highly multidisciplinary, bridging the knowledge gap between tumor biology, nanotechnology, and diagnostic imaging, and thus making it suitable for researchers ranging from oncology to bioengineering. Although considerable efforts have been conducted to diagnose, improve and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. One of the best hopes for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase our current understanding of tumor biology, allowing nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models.

Inflammation and Oral Cancer: From Bench to Bedside discusses all aspects surrounding the relationship between inflammation and oral cancer, from basic science to the translational research that helps in the optimization of clinical management strategies. The book discusses topics such as chronic inflammation and cancer in oral cavity, the role of HPV in oral inflammation and cancer, rodent models of oral cancer, and epigenetics in oral inflammation and cancer. This is a valuable resource for cancer researchers, oncologists and members of biomedical field who are interested in learning more about the diverse aspects of inflammation and oral cancer. Inflammation in oral mucosa can remodel the topography of the overlying epithelium. If such inflammation is chronic, it can have fundamental clinical consequences, the principal of which can be premalignant lesions throughout the alimentary tract. Furthermore, mucosal inflammation, even if subtle, is the single most common pathway for oral cancer - therefore it is very important to understand these interactions in detail.

Advances in Cancer Research, Volume 152, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.

Nanotherapeutics in Cancer Vaccination and Challenges consolidates the current research on cancer nanomedicine and therapeutic cancer vaccination to explore the most effective and promising avenues. The book covers cancer vaccines before exploring nanotherapeutics, DNA and mRNA vaccines in cancer treatment. Finally, it considers regulatory and industrial perspectives on cancer vaccination and nanotherapeutics. This resource will be useful for pharmaceutical scientists and researchers focused on biomedical engineering, chemical engineering, vaccine development, and cancer immunotherapy, along with advanced students in these subjects. Cancer is arguably the most complex and challenging disease known to mankind. Over the last two-decades, significant advancements have been made in new and novel concepts of cancer nanomedicines. Therapeutic cancer vaccines may be utilized to inhibit further growth of advanced cancers and/or relapsed tumors that are refractory to conventional therapies, such as surgery, radiation therapy and chemotherapy.

Advances in Cancer Biomarkers Research provides a thorough and detailed description of cancer biomarkers for diagnostic, prognostic and therapeutics in several cancer types. The book presents a compendium of topics related to current advanced research, along with fundamental knowledge that will help readers fully comprehend the field of cancer biomarkers. Topics discussed include such the role of genetic mechanisms, epigenetics, DNA and microRNA in different cancers, signaling pathways and exosomes. In addition, the book discusses biomarker research applied to several cancer types, such as head and neck, urological, lung, bone tumors, hematological and neurological malignancies and breast cancers.This will be a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of biomarkers in cancer research and treatment.

Starving Cancer Cells: Evidence-Based Strategies to Slow Cancer Progression - A Selection of Readings for Health Services Providers presents an edited and annotated collection of recent medical journal publications and abstracts illustrating new approaches to treatment derived from the metabolic theory of cancer. It intends to shed an early light on a relatively new approach to our understanding of the cancer cell idiosyncratic metabolic dysfunction, and on evidence-based new treatment strategies derived from that understanding. The book discusses topics such as tumor starvation by L-arginine deprivation; L-canavanine depriving tumors of L-arginine in pancreatic, multiple myeloma and breast cancer; glucose deprivation and intermittent fasting; glutamine uptake in cancer; the relation of oxygen-starved cancer cells with aspartate; and reducing tolerance of tumor cells to nutrition starvation. The content is presented in a contextualized and practical way in order to facilitate the transition from bench to bedside. This is a valuable resource for practitioners, oncologists and other members of healthcare chain who are interested in learning more about the most recent tumor cell starvation strategies and how they can improve overall treatment outcome.